Refine
Document Type
- Article (11)
- Doctoral Thesis (1)
Has Fulltext
- yes (12)
Is part of the Bibliography
- no (12)
Keywords
- - (7)
- hepatocellular carcinoma (4)
- AFH (1)
- Amitriptylin (1)
- CCR2 (1)
- Carbohydrate metabolism (1)
- ChREBP (1)
- Chronic liver disease (1)
- DLC1 (1)
- Endothel (1)
Institute
- Institut für Pathologie (7)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Biometrie und Medizinische Informatik (1)
- Institut für Diagnostische Radiologie und Neuroradiologie (1)
- Klinik für Anästhesiologie und Intensivmedizin (1)
- Klinik für Herz-, Thorax- und Gefäßchirurgie - Klinikum Karlsburg (1)
Publisher
- MDPI (7)
- BMJ Publishing Group (1)
- Frontiers Media S.A. (1)
- Wiley (1)
- Xia & He Publishing (1)
Einleitung: In dieser Studie wurden die antidepressiv wirksamen Medikamente Amitriptylin, Fluoxetin, Tranylcypromin und Venlafaxin auf ihre peripheren vasoaktiven Eigenschaften hin untersucht, da sie in der klinischen Anwendung häufig zu Blutdruckveränderungen führen. Material und Methoden: Es wurden in-vitro-Untersuchungen an endothelintakten und endothelfreien Rattenaorten durchgeführt. Wir ermittelten die Effekte der Antidepressiva in kumulativer Dosierung auf mittels KCl, Phenylephrin und Prostaglandin F2α präkontrahierte Aortenringe. Weiterhin wurden die zugrunde liegenden vasoaktiven Mechanismen im Hinblick auf die NO cGMP-Signaltransduktion, den second-messenger cAMP und die Beteiligung von K+ Kanälen sowie Adrenozeptoren näher untersucht. Ergebnisse: Alle vier Antidepressiva haben direkte Effekte auf die Rattenaorta in vitro. Sie dilatieren konzentrationsabhängig vorkontrahierte Aortenringe; pEC50 nach Vorkontraktion mit Phenylephrin (0,1 µM): Amitriptylin (6,98±0,13), Fluoxetin (6,11±0,05), Tranylcypromin (5,33±0,05), Venlafaxin (4,45±0,08) (n=8); mit KCl (20 mM): Amitriptylin (4,89±0,11), Fluoxetin (6,00±0,06), Tranylcypromin (4,99±0,30), Venlafaxin (5,02±0,07) (n=7). Hohe Konzentrationen an Tranylcypromin führen nach Vorkontraktion mit PGF2α zu einer weiteren Kontraktion endothelintakter Aorten. Gegenüber den Kontrollexperimenten führte die Hemmung des NO-cGMP-Signalweges, der cAMP-Produktion sowie die Blockade von K+-Kanälen und Adrenozeptoren zu Verschiebungen der Dosis-Antwort-Kurven der Antidepressiva. Amitriptylin, Fluoxetin und Venlafaxin hemmen die Kontraktionsantwort von Aortenringen auf adrenerge Einflüsse, Tranylcypromin verstärkt diese hingegen. Diskussion: Amitriptylin interagiert mit der pharmakomechanischen Kopplung im glatten Gefäßmuskel, indem es die Aortenringe durch eine antagonistische Wirkung an α1 Adrenozeptoren relaxiert. Auch Venlafaxin interagiert mit Adrenozeptoren. Fluoxetin, Tranylcypromin und Venlafaxin wirken über die elektromechanische Kopplung durch eine K+-Kanal-Aktivierung vasodilatierend. Die Relaxation der glatten Gefäßmuskulatur durch die antidepressiven Medikamente ist teilweise abhängig von der Integrität des Endothels, da insbesondere eine Aktivierung der endothelabhängigen Induktion der NO-cGMP-Signalkaskade durch die Antidepressiva stattfindet. Die zusätzlich vasokonstriktive Wirkung von Tranylcypromin lässt sich durch seine bekannte Interaktion mit dem Prostaglandin-Stoffwechsel erklären. Die Relaxation der Rattenaorta in vitro und das Auftreten hypotensiver Verläufe bei klinischer Anwendung der untersuchten Antidepressiva kann durch die in dieser Studie gezeigten direkten peripheren vaskulären Effekte dieser Medikamente mit erklärt werden.
Simple Summary
Hepatocellular carcinoma (HCC) ranks second among the leading causes of cancer-related death. Since current therapeutic options are very limited, a deeper understanding of the molecular mechanisms underlying the tumor onset and progression of HCC holds great potential for improved therapeutic options. Although it has been shown that deleted in liver cancer 1 (DLC1) acts as a tumor suppressor whose allele is lost in 50% of liver cancers, alterations in gene expression initiated by DLC1 loss have not yet been the primary focus of liver cancer research. To identify novel gene targets that allow for a personalized medicine approach for HCC therapy, we performed gene expression profiling for HepG2 cells stably expressing DLC1shRNA. We provide evidence that TSPAN5 is required for HCC growth, migration and invasion, and dissected the underlying molecular mechanisms involving myocardin-related transcription factors. Thus, TSPAN5 represents a novel therapeutic target for the treatment of HCC characterized by DLC1 loss.
Abstract
Human hepatocellular carcinoma (HCC) is among the most lethal and common cancers in the human population, and new molecular targets for therapeutic intervention are urgently needed. Deleted in liver cancer 1 (DLC1) was originally identified as a tumor suppressor gene in human HCC. DLC1 is a Rho-GTPase-activating protein (RhoGAP) which accelerates the return of RhoGTPases to an inactive state. We recently described that the restoration of DLC1 expression induces cellular senescence. However, this principle is not amenable to direct therapeutic targeting. We therefore performed gene expression profiling for HepG2 cells depleted of DLC1 to identify druggable gene targets mediating the effects of DLC1 on senescence induction. This approach revealed that versican (VCAN), tetraspanin 5 (TSPAN5) and N-cadherin (CDH2) were strongly upregulated upon DLC1 depletion in HCC cells, but only TSPAN5 affected the proliferation of HCC cells and human HCC. The depletion of TSPAN5 induced oncogene-induced senescence (OIS), mediated by the p16INK4a/pRb pathways. Mechanistically, silencing TSPAN5 reduced actin polymerization and thereby myocardin-related transcription factor A- filamin A (MRTF-A-FLNA) complex formation, resulting in decreased expression of MRTF/SRF-dependent target genes and senescence induction in vitro and in vivo. Our results identify TSPAN5 as a novel druggable target for HCC.
Objective: In the rat, the pancreatic islet transplantation model is an established method to induce hepatocellular carcinomas (HCC), due to insulin-mediated metabolic and molecular alterations like increased glycolysis and de novo lipogenesis and the oncogenic AKT/mTOR pathway including upregulation of the transcription factor Carbohydrate-response element-binding protein (ChREBP). ChREBP could therefore represent an essential oncogenic co-factor during hormonally induced hepatocarcinogenesis. Methods: Pancreatic islet transplantation was implemented in diabetic C57Bl/6J (wild type, WT) and ChREBP-knockout (KO) mice for 6 and 12 months. Liver tissue was examined using histology, immunohistochemistry, electron microscopy and Western blot analysis. Finally, we performed NGS-based transcriptome analysis between WT and KO liver tumor tissues. Results: Three hepatocellular carcinomas were detectable after 6 and 12 months in diabetic transplanted WT mice, but only one in a KO mouse after 12 months. Pre-neoplastic clear cell foci (CCF) were also present in liver acini downstream of the islets in WT and KO mice. In KO tumors, glycolysis, de novo lipogenesis and AKT/mTOR signalling were strongly downregulated compared to WT lesions. Extrafocal liver tissue of diabetic, transplanted KO mice revealed less glycogen storage and proliferative activity than WT mice. From transcriptome analysis, we identified a set of transcripts pertaining to metabolic, oncogenic and immunogenic pathways that are differentially expressed between tumors of WT and KO mice. Of 315 metabolism-associated genes, we observed 199 genes that displayed upregulation in the tumor of WT mice, whereas 116 transcripts showed their downregulated expression in KO mice tumor. Conclusions: The pancreatic islet transplantation model is a suitable method to study hormonally induced hepatocarcinogenesis also in mice, allowing combination with gene knockout models. Our data indicate that deletion of ChREBP delays insulin-induced hepatocarcinogenesis, suggesting a combined oncogenic and lipogenic function of ChREBP along AKT/mTOR-mediated proliferation of hepatocytes and induction of hepatocellular carcinoma.
Simple Summary
The tumor suppressor protein P53 is a major player in preventing liver cancer development and progression. In this study we could show that P53 negatively regulates the expression of Helicase, lymphoid specific (HELLS), previously described as an important pro-tumorigenic epigenetic regulator in hepatocarcinogenesis. The regulatory mechanism included induction of the P53 target gene P21 (CDKN1A) resulting in repression of HELLS via downregulation of the transcription factor Forkhead Box Protein M1 (FOXM1). Our in vitro and in vivo findings indicate an important additional aspect of the tumor suppressive function of P53 in liver cancer linked to epigenetic regulation.
Abstract
The major tumor suppressor P53 (TP53) acts primarily as a transcription factor by activating or repressing subsets of its numerous target genes, resulting in different cellular outcomes (e.g., cell cycle arrest, apoptosis and senescence). P53-dependent gene regulation is linked to several aspects of chromatin remodeling; however, regulation of chromatin-modifying enzymes by P53 is poorly understood in hepatocarcinogenesis. Herein, we identified Helicase, lymphoid specific (HELLS), a major epigenetic regulator in liver cancer, as a strong and selective P53 repression target within the SNF2-like helicase family. The underlying regulatory mechanism involved P53-dependent induction of P21 (CDKN1A), leading to repression of Forkhead Box Protein M1 (FOXM1) that in turn resulted in downregulation of HELLS expression. Supporting our in vitro data, we found higher expression of HELLS in murine HCCs arising in a Trp53−/− background compared to Trp53+/+ HCCs as well as a strong and highly significant correlation between HELLS and FOXM1 expression in different HCC patient cohorts. Our data suggest that functional or mutational inactivation of P53 substantially contributes to overexpression of HELLS in HCC patients and indicates a previously unstudied aspect of P53′s ability to suppress liver cancer formation.
Hepatocellular carcinoma (HCC) is a deadly form of liver malignancy with limited treatment
options. Amplification and/or overexpression of c-MYC is one of the most frequent genetic events
in human HCC. The mammalian target of Rapamycin Complex 1 (mTORC1) is a major functional
axis regulating various aspects of cellular growth and metabolism. Recently, we demonstrated that
mTORC1 is necessary for c-Myc driven hepatocarcinogenesis as well as for HCC cell growth in vitro.
Among the pivotal downstream effectors of mTORC1, upregulation of Fatty Acid Synthase (FASN) and
its mediated de novo lipogenesis is a hallmark of human HCC. Here, we investigated the importance
of FASN on c-Myc-dependent hepatocarcinogenesis using in vitro and in vivo approaches. In mouse
and human HCC cells, we found that FASN suppression by either gene silencing or soluble inhibitors
more effectively suppressed proliferation and induced apoptosis in the presence of high c-MYC
expression. In c-Myc/Myeloid cell leukemia 1 (MCL1) mouse liver tumor lesions, FASN expression
was markedly upregulated. Most importantly, genetic ablation of Fasn profoundly delayed (without
abolishing) c-Myc/MCL1 induced HCC formation. Liver tumors developing in c-Myc/MCL1 mice
depleted of Fasn showed a reduction in proliferation and an increase in apoptosis when compared
with corresponding lesions from c-Myc/MCL1 mice with an intact Fasn gene. In human HCC samples,
a significant correlation between the levels of c-MYC transcriptional activity and the expression
of FASN mRNA was detected. Altogether, our study indicates that FASN is an important effector
downstream of mTORC1 in c-MYC induced HCC. Targeting FASN may be helpful for the treatment
of human HCC, at least in the tumor subset displaying c-MYC amplification or activation.
EGFR is overexpressed in the majority of clear cell renal cell carcinomas (CCRCCs). Although EGFR deregulation was found to be of great significance in CCRCC biology, the EGFR
overexpression is not associated with EGFR-targeted therapy responsiveness. Moreover, the prognostic role of EGFR expression remains controversial. In the present study, we evaluated the role
played by EGFR overexpression in CCRCC and its prognostic significance associated with different
immunohistochemical localization patterns. In our study, the Total Score (TS) related to membranouscytoplasmic EGFR expression showed a significant correlation with grade, pathologic stage (pT),
and Stage, Size, Grade, and Necrosis (SSIGN) score, and a negative correlation with nuclear EGFR
expression. No significant correlations were shown between nuclear EGFR and clinic-pathological
features. Additionally, a correlation between SGLT1 expression levels and pT was described. Multivariate analysis identifies pT and SSIGN score as independent prognostic factors for CCRCC. A
significantly increased survival rate was found in the case of positive expression of nuclear EGFR
and SGLT1. Based on our findings, SGLT1 and nuclear EGFR overexpression defines a subgroup of
CCRCC patients with good prognosis. Membranous-cytoplasmic EGFR expression was shown to be
a poor prognostic factor and could define a CCRCC subgroup with poor prognosis that should be
responsive to anti-EGFR therapies
Increasing the information depth of single kidney biopsies can improve diagnostic precision, personalized medicine and accelerate basic kidney research. Until now, information on mRNA abundance and morphologic analysis has been obtained from different samples, missing out on the spatial context and single-cell correlation of findings. Herein, we present scoMorphoFISH, a modular toolbox to obtain spatial single-cell single-mRNA expression data from routinely generated kidney biopsies. Deep learning was used to virtually dissect tissue sections in tissue compartments and cell types to which single-cell expression data were assigned. Furthermore, we show correlative and spatial single-cell expression quantification with super-resolved podocyte foot process morphometry. In contrast to bulk analysis methods, this approach will help to identify local transcription changes even in less frequent kidney cell types on a spatial single-cell level with single-mRNA resolution. Using this method, we demonstrate that ACE2 can be locally upregulated in podocytes upon injury. In a patient suffering from COVID-19-associated collapsing FSGS, ACE2 expression levels were correlated with intracellular SARS-CoV-2 abundance. As this method performs well with standard formalin-fixed paraffin-embedded samples and we provide pretrained deep learning networks embedded in a comprehensive image analysis workflow, this method can be applied immediately in a variety of settings.
ObjectiveLarge-scale genome sequencing efforts of human tumours identified epigenetic modifiers as one of the most frequently mutated gene class in human cancer. However, how these mutations drive tumour development and tumour progression are largely unknown. Here, we investigated the function of the histone demethylase KDM6A in gastrointestinal cancers, such as liver cancer and pancreatic cancer.DesignGenetic alterations as well as expression analyses of KDM6A were performed in patients with liver cancer. Genetic mouse models of liver and pancreatic cancer coupled with Kdm6a-deficiency were investigated, transcriptomic and epigenetic profiling was performed, and in vivo and in vitro drug treatments were conducted.ResultsKDM6A expression was lost in 30% of patients with liver cancer. Kdm6a deletion significantly accelerated tumour development in murine liver and pancreatic cancer models. Kdm6a-deficient tumours showed hyperactivation of mTORC1 signalling, whereas endogenous Kdm6a re-expression by inducible RNA-interference in established Kdm6a-deficient tumours diminished mTORC1 activity resulting in attenuated tumour progression. Genome-wide transcriptional and epigenetic profiling revealed direct binding of Kdm6a to crucial negative regulators of mTORC1, such as Deptor, and subsequent transcriptional activation by epigenetic remodelling. Moreover, in vitro and in vivo genetic epistasis experiments illustrated a crucial function of Deptor and mTORC1 in Kdm6a-dependent tumour suppression. Importantly, KDM6A expression in human tumours correlates with mTORC1 activity and KDM6A-deficient tumours exhibit increased sensitivity to mTORC1 inhibition.ConclusionKDM6A is an important tumour suppressor in gastrointestinal cancers and acts as an epigenetic toggle for mTORC1 signalling. Patients with KDM6A-deficient tumours could benefit of targeted therapy focusing on mTORC1 inhibition.
An aneurysmal fibrous histiocytoma is a rare cutaneous soft-tissue tumour which accounts for approximately 0.06% of all dermatopathologies. Metastasis is exceedingly uncommon, to the point that there have only been eight reported cases in the scientific literature. We present the case of a 25-year-old male with a primary aneurysmal fibrous histiocytoma located in the nuchal region which exhibited rapid growth and abrupt ulceration over a short time span and showed signs of locoregional aggressive infiltration. A subsequent histopathological analysis confirmed the presence of diffuse solid and cystic pulmonary metastases. Further genetic sequencing verified LAMTOR1-PRKCD fusion. This case report seeks to review the existing literature on aneurysmal fibrous histiocytoma, discuss the challenges of differential diagnosis and propose standardised diagnostic criteria.